DEFI-ALPHA cohort and POLYGEN DEFI-ALPHA clinical research hospital programme. A study about clinical, biological and genetics factors associated with the occurrence and the evolution of hepatic complications in children with alpha-1 antitrypsin deficiency;Cohorte DEFI-ALPHA et projet hospitalier de recherche clinique POLYGEN DEFI-ALPHA. Étude des facteurs cliniques, biologiques et génétiques associés à l'apparition et à l'évolution de complications hépatiques chez les enfants présentant un déficit en alpha-1 antitrypsine

Revue des Maladies Respiratoires

Volumn 32, Issue 7, 2015, Pages 759-767

  Joly, P ^a   Restier, L ^a   Bouchecareilh, M ^b   Lacan, P ^a   Cabet, F ^a   Chapuis Cellier, C ^a   Francina, A ^a   Lachaux, A ^a  

^a UNIVERSITÉ LYON 1   (France)

^b Institut de Biochimie et Genetique Cellulaires   (France)

Author keywords

Alpha 1 antitrypsin; Cirrhosis; Modifying genes; Pediatric multicentric cohort; Portal hypertension

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; MAN1B1 PROTEIN; PROTEIN; SERPINA1 PROTEIN; SORL1 PROTEIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; CLINICAL RESEARCH; COHORT ANALYSIS; DISEASE DURATION; DNA POLYMORPHISM; GENETIC ASSOCIATION; GENETIC PROCEDURES; HEREDITY; HUMAN; JAUNDICE; LIVER FIBROSIS; PORTAL HYPERTENSION; PROSPECTIVE STUDY; PROTEIN DEGRADATION; WHOLE EXOME SEQUENCING; ADOLESCENT; ALPHA 1-ANTITRYPSIN DEFICIENCY; DISEASE COURSE; FEMALE; GENETIC PREDISPOSITION; GENETICS; HOSPITAL; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MEDICAL RESEARCH; METHODOLOGY; PATHOLOGY; PATIENT SELECTION; PRESCHOOL CHILD; RISK FACTOR; STANDARDS; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ALPHA 1-ANTITRYPSIN DEFICIENCY; BIOMEDICAL RESEARCH; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOSPITALS; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; PATIENT SELECTION; RESEARCH DESIGN; RISK FACTORS;

EID: 84941741069     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2015.06.010     Document Type: Article

References (35)

1. 1] Stoller JK, Aboussouan LS. A review of alpha-1 antitrypsin defi-ciency. Am J Respir Crit Care Med 2012;185:246-59.
2. 2] Stoller JK, Aboussouan LS. Alpha-1 antitrypsin deficiency. Lan-cet 2005;365:2225-36.
3. 3] Fregonese L, Stolk J. Hereditary alpha-1-Antitrypsin deficiencyand its clinical consequences. Orphanet J Rare Dis 2008;3:16.
4. Perlmutter DH. Alpha-1-Antitrypsin deficiency: importance ofproteasomal and autophagic degradative pathways in disposalof liver disease-Associated protein aggregates. Annu Rev Med2011 62 333-45.
5. 5] Silverman GA, Pak SC, Perlmutter DH. Disorders of protein mis-folding: alpha-1-Antitrypsin deficiency as prototype. J Pediatr2013;163:320-6.
6. 6] Sveger T. Liver disease in alpha 1 anti-trypsin deficiencydetected by screening of 200,000 infants. N Engl J Med1976;294:1316-21.
7. 7] Teckman J, Pardee E, Howell RR, et al. Appropriateness ofnewborn screening for-1-Antitrypsin deficiency. J Pediatr Gas-troenterol Nutr 2014;58:201-5.
8. 8] Sveger T. The natural history of liver disease in alpha 1-Antitrypsin deficient children. Acta Paediatr Scand 1988;77:847-51.
9. 9] Sharp HL. Wherefore art thou liver disease associatedwith alpha-1 antitrypsin deficiency. Hepatology 1995;22:666-8.
10. De Franchis R. Updating consensus in portal hypertension:report of the Baveno III consensus w orkshop on definitions,methodology and therapeutic strategies in portal hypertension.J Hepatol 2000;33:846-52.
11. Lapalus MG, Ben Soussan E, Gaudric M, et al. Esophagealcapsule endoscopy vs EGD for the evaluation of portal hyper-tension: a French prospective multicenter comparative study.Am J Gastroenterol 2009;104:1112-8.
12. Perlmutter DH, Silverman GA. Hepatic fibrosis and carcino-genesis in-1-Antitrypsin deficiency: a prototype for chronictissue damage in gain-of-function disorders. Cold Spring HarbPerspect Biol 2011;3:1-14.
13. Chappell S, Daly L, Morgan K, et al. Cryptic haplotypes of SER-PINA1 confer susceptibility to chronic obstructive pulmonarydisease. Hum Mutat 2006;27:103-9.
14. Chappell S, Hadzic N, Stockley R, et al. A polymorphism ofthe alpha-1 antitrypsin gene represents a risk factor for liverdisease. Hepatology 2008;47:127-32.
15. Teckman JH. Liver disease in alpha-1 antitrypsin defi-ciency: current understanding and future therapy. COPD2013;10:35-43.
16. Kok KF, te Morsche RH, Van Oijen MG, et al. Prevalence ofgenetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a casecontrol study. BMC Gastroenterol 2010;10:22.
17. Greene CM, McElvaney NG. Z-Antitrypsin deficiency and theendoplasmic reticulum stress response. World J GastrointestPharmacol Ther 2010;1:94-101.
18. Rymen D, Peanne R, Millon MB, et al. MAN1B1 deficiency: anunexpected CDG (congenital disorders of glycosylation)-II. PLoSGenet 2013;9:1-13.
19. Iannoti MJ, Figard L, Sokac AM, et al. A Golgi-localizedmannosidase (MAN1B1) plays a non-enzymatic gatekeeperrole in protein biosynthetic quality control. J Bi ol Chem2014;289:11844-58.
20. Liu Y, Choudhury P, Cabral CM, et al. Oligosaccharide modifi-cation in the early secretory pathway directs the selection ofa misfolded glycoprotein for degradation by the pr oteasome. JBiol Chem 1999;274:5861-7.
21. Pan S, Huang L, McPherson J, et al. Single nucleotidepolymorphism-mediated translational suppression of endoplas-mic reticulum mannosidase I modifies the ons et of end-stageliver disease in alpha-1-Antitrypsin deficiency. Hepatology2009;50:275-81.
22. Chappell S, Hadzic N, Stockley R, et al. Polymorphism in theendoplasmic reticulum mannosidase I (MAN1B1) gene is notassociated with liver disease in individuals homozygous for theZ variant of the alpha-1 antitrypsin protease inhibitor (PiZZindividuals). Hepatology 2009;50:1315.
23. Nash KL, Allison ME, McKeon D , et al. A single centre experienceof liver disease in adults with cystic fibrosis 1995-2006. J CystFibros 2008;7:252-7.
24. Bartlett JR, Friedman KJ, Ling SC, et al. Genetic modifiers ofliver disease in cystic fibrosis. JAMA 2009;302:1076-83.
25. Yin C,Evason KJ,Asahina K,et al. Hepatic stellate cells inliver development regeneration and cancer J Clin Invest2013 135 1902-10.
26. Ghouse R, Chu A, Wang Y, et al. Mysteries of-Antitrypsindeficiency: emerging therapeutic strategies for a challengingdisease. Dis Model Mech 2014;7:411-9.
27. Valastyan JS, Lindquist S. Mechanisms of protein-foldingdiseases at a glance. Dis Model Mech 2014;7:9-14.
28. Gelling CL, Dawes IW, Perlmutter DH, et al. The endosomalprotein-sorting receptor sortilin has a role in trafficking-Antitrypsin. Genetics 2012;192:889-903.
29. Willnow TE, Andersen OM. Sorting receptor SORLA-A traf-ficking path to avoid Alzheimer disease. J Cell Sci 2013;126:2751-60.
30. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-relatedreceptor SORL1 is genetically associated with Alzheimerdisease. Nat Genet 2007;39:168-77.
31. Liu F, Arias-Vasquez A, Sleegers K, et al. A genomewide screenfor late-onset Alzheimer disease in a genetically isolated Dutchpopulation. Am J Hum Genet 2007;81:17-31.
32. Lee JH, Cheng R, Honig LS, et al. Association between gene-tic variants in SORL1 and autopsy-confirmed Alzheimer disease.Neurology 2008;70:887-9.
33. Cellini E, Tedde A, Bagnoli S, et al. Implication of sex andSORL1 variants in italian patients with Alzheimer disease. ArchNeurol 2009;66:1260-6.
34. Tan EK, Lee J, Chen CP, et al. SORL1 haplotypes modu-late risk of Alzheimer's disease in Chinese. Neurobiol Aging2009;30:1048-51.
35. Reitz C, Tokuhi ro S, Clark LN, et al. SORCS1 alters amyloidprecursor protein processing and variants may increase Alz-heimer's disease risk. Ann Neurol 2011;69:47-64.